TARDBP and hereditary spastic paraplegia: Advances in assay development—particularly those targeting phosphorylated or truncated forms of TDP-43—may eventually enable its inclusion in multimodal biomarker strategies aimed at refining diagnosis, tracking progression, or stratifying phenotypes within the heterogeneous spectrum of HSP [81].